Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes.
Br. J. Haematol., Dec;159(5):572-6 (2012)
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
Leuk. Lymphoma., Aug (2012)
Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Cancer., Jul (2012)
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.
Blood., Jul;120(4):843-6 (2012)
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Cancer., Apr;118(7):1827-37 (2012)
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.
Leukemia., Sep;25(9):1459-66 (2011)
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
Blood., Feb;117(6):1911-6 (2011)
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.
Br. J. Haematol., Oct;151(2):152-8 (2010)
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.
Nat. Genet., Aug;42(8):661-4 (2010)
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Blood., Apr;115(16):3416-7 (2010)
Genetic susceptibility variants for chronic lymphocytic leukemia.
Cancer Epidemiol. Biomarkers Prev., Apr;19(4):1098-102 (2010)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Leukemia., Jul;23(7):1337-41 (2009)
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Blood., Oct;110(7):2744-8 (2007)
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
Cytometry B Clin Cytom., May;72(3):189-95 (2007)
Isolation in the allogeneic transplant environment: how protective is it?
Bone Marrow Transplant., Sep;36(5):373-81 (2005)
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Haematologica., Sep;89(9):ECR30 (2004)
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Leuk. Lymphoma., Apr;45(4):695-8 (2004)